Consequently, future approaches to treatment targeting in MPNs and acute leukemia should also concentrate on and exploit the antioxidant and anti-inflammatory properties of current MPN medication, e.g., ropeginterferon alpha-2b or JAK1/2 inhibition, as well as potentially synthesize novel compounds from natural products that exhibit these properties when available [106,107,108,109,110,111]. This evidence concerns the gene JAK1 and myeloproliferative disorder.